deferasirox · Novartis Pharms Corp · NDA 206910
Jadenu
Earliest generic entry, as listed · earliest of 3 marketed strengths
21 Nov 2034
Blocked by patent: US 9283209.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9283209 | substance, product | 21 Nov 2034 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206910 · 001 · RLD | tablet, oral | 90MG | 21 Nov 2034 |
| 206910 · 002 · RLD | tablet, oral | 180MG | 21 Nov 2034 |
| 206910 · 003 · RLD | tablet, oral | 360MG | 21 Nov 2034 |